Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon α
作者： J. Wiegand , K. Deterding , M. Cornberg , H. Wedemeyer
DOI: 10.1093/JAC/DKN346
关键词:
摘要: Early control in the acute phase of hepatitis C infection is an attractive therapeutic goal order to shorten disease duration and infectivity, prevent chronicity progression advanced liver avoid eventual non-response later stages chronic C. Over past decade, different interferon-based treatment options have been developed, which lead sustained virological response rates up 98%. The present article summarizes successful invention immediate delayed strategies monoinfection, critically discusses potential limitations illustrates challenges near future.
oup.com
oxfordjournals.org
sci-hub.se 参考文章(61)
H.L. Tillmann, C. Bader, S. Kuhn, M.P. Manns, H. Wedemeyer, A. Kubitschke, Verletzungen mit Hepatitis-C-Virus-kontaminierten Nadeln Der Internist. ,vol. 48, pp. 1165- 1172 ,(2007) , 10.1007/S00108-007-1912-Z
H L Tillmann, C Bader, S Kuhn, H Wedemeyer, A Kubitschke, M P Manns, [Injuries from needles contaminated with hepatitis C virus: how high is the risk of seroconversion for medical personnel really?]. Der Internist. ,vol. 48, pp. 1165- 1172 ,(2007) , 10.1007/S00108-007-1912-Z
J.Tilman Gerlach, Helmut M Diepolder, Reinhart Zachoval, Norbert H Gruener, Maria-Christina Jung, Axel Ulsenheimer, Winfried W Schraut, C.albrecht Schirren, M Waechtler, M Backmund, Gerd R Pape, Acute Hepatitis C: High Rate of Both Spontaneous and Treatment-Induced Viral Clearance Gastroenterology. ,vol. 125, pp. 80- 88 ,(2003) , 10.1016/S0016-5085(03)00668-1
M. E. Tosti, S. Solinas, D. Prati, L. Salvaneschi, M. Manca, M. Francesconi, M. Ciuffreda, G. Girelli, A. Mele, An estimate of the current risk of transmitting blood‐borne infections through blood transfusion in Italy British Journal of Haematology. ,vol. 117, pp. 215- 219 ,(2002) , 10.1046/J.1365-2141.2002.03334.X
Heiner Wedemeyer, Markus Cornberg, Johannes Wiegand, Michael Manns, Treatment duration in acute hepatitis C: The issue is not solved yet Hepatology. ,vol. 44, pp. 1051- 1051 ,(2006) , 10.1002/HEP.21348
Alessandra Mangia, Rosanna Santoro, Nicola Minerva, Giovanni L. Ricci, Vito Carretta, Marcello Persico, Francesco Vinelli, Gaetano Scotto, Donato Bacca, Mauro Annese, Mario Romano, Franco Zechini, Fernando Sogari, Fulvio Spirito, Angelo Andriulli, Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. The New England Journal of Medicine. ,vol. 352, pp. 2609- 2617 ,(2005) , 10.1056/NEJMOA042608
Stefan Zeuzem, Maria Buti, Peter Ferenci, Jan Sperl, Yves Horsmans, Janusz Cianciara, Endre Ibranyi, Ola Weiland, Stephanie Noviello, Clifford Brass, Janice Albrecht, Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia Journal of Hepatology. ,vol. 44, pp. 97- 103 ,(2006) , 10.1016/J.JHEP.2005.10.003
T Santantonio, E Sinisi, A Guastadisegni, C Casalino, M Mazzola, A Gentile, G Leandro, G Pastore, Natural course of acute hepatitis C: a long-term prospective study. Digestive and Liver Disease. ,vol. 35, pp. 104- 113 ,(2003) , 10.1016/S1590-8658(03)00007-0
H Hofer, Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load Hepatology. ,vol. 37, pp. 60- 64 ,(2003) , 10.1053/JHEP.2003.50019
Michael von Wagner, Miriam Huber, Thomas Berg, Holger Hinrichsen, Jens Rasenack, Tobias Heintges, Alexandra Bergk, Christine Bernsmeier, Dieter Häussinger, Eva Herrmann, Stefan Zeuzem, Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C Gastroenterology. ,vol. 129, pp. 522- 527 ,(2005) , 10.1053/J.GASTRO.2005.05.008